Clinical trial
Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in…
NCT00245388 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00245388 |
|---|---|
| Title | Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia |
| Official title | A Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Trial to Determine the Lipid-Lowering Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Dyslipidemia |
| Intervention type | Drug |
| Interventions | Muraglitazar |
| Enrollment | 330 |
| Start date | Apr 1, 2002 |
| Completion | Jul 1, 2002 |
| First posted | Oct 28, 2005 |
| Last update posted | Apr 23, 2012 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: